<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305809</url>
  </required_header>
  <id_info>
    <org_study_id>16261</org_study_id>
    <secondary_id>I7S-MC-HBEH</secondary_id>
    <nct_id>NCT03305809</nct_id>
  </id_info>
  <brief_title>A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)</brief_title>
  <acronym>PRESENCE</acronym>
  <official_title>Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of
      study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia
      associated with LBD (PDD or DLB).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">July 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the CoA composite score of the CDR-CCB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline on the ADCS-CGIC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the CDR-CCB Power of Attention (PoA) Composite Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline on the CDR-CCB PoA composite score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog13)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the 13-item ADAS-Cog13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Screening in the Montreal Cognitive Assessment (MoCA) Score</measure>
    <time_frame>Screening, Week 12</time_frame>
    <description>Change from Screening in the MoCA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Neuropsychiatric Inventory (NPI) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the NPI total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Epworth Sleepiness Scale (ESS) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the ESS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the MDS-UPDRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the PDAQ-15 total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in D-KEFS verbal fluency test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure (SBP) to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in SBP to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SBP to 8 Hours Post Dose</measure>
    <time_frame>Baseline, 8 Hours Post Dose</time_frame>
    <description>Change from baseline in SBP to 8 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in pulse rate to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate to 8 Hours Post Dose</measure>
    <time_frame>Baseline, 8 Hours Post Dose</time_frame>
    <description>Change from baseline in pulse rate to 8 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Week 12 in the Physician Withdrawal Checklist (PWC)-20 Total Score</measure>
    <time_frame>Week 12, Follow-up (2 Days after Week 12 Visit)</time_frame>
    <description>Change from week 12 in PWC-20 to Follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Steady-State Trough Plasma Concentrations of LY3154207</measure>
    <time_frame>Week 12</time_frame>
    <description>PK: Steady-State Trough Plasma Concentrations of LY3154207</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Lewy Body Dementia</condition>
  <arm_group>
    <arm_group_label>LY3154207 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3154207</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3154207 High Dose</arm_group_label>
    <arm_group_label>LY3154207 Low Dose</arm_group_label>
    <arm_group_label>LY3154207 Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have dementia as defined by a decline in cognitive function, which in the opinion of
             the investigator has resulted in functional impairment.

          -  Meet diagnostic criteria for PD per MDS criteria or DLB per 4th Consensus Report of
             the DLB Consortium.

          -  Have a score on the MoCA of 10 - 23.

          -  Are Modified Hoehn and Yahr Stages 0 - 4.

          -  Have a blood pressure (BP) or pulse rate at screening and randomization, as determined
             by three sequential BP/pulse rate measurements in a seated position:

               -  Participants &lt;60 years old:

                    1. A mean systolic BP less than or equal to 140 millimeters of mercury (mmHg),
                       a mean diastolic BP less than or equal to 90 mmHg and a mean pulse rate less
                       than or equal 90 beats/minute in a seated position.

                    2. Each of the 3 systolic BP measurement must be less than 180 mmHg

               -  Participants ≥60 years old:

                    1. A mean systolic BP less than or equal to 150 mmHg, a mean diastolic BP less
                       than or equal to 90 mmHg and a mean pulse rate less than or equal to 90
                       beats/min in a seated position.

                    2. Each of the 3 systolic BP measurement must be less than 180 mmHg

          -  If on anti-parkinsonian agents, participants must be on stable dosage for at least 3
             weeks prior to screening, and should remain on stable doses during the course of the
             study.

          -  If on medications affecting cognition (rivastigmine, galantamine, donepezil,
             memantine), participants must be on stable dosage for at least 3 weeks prior to
             screening and should remain at a stable dosage during the course of the study.

          -  If on antidepressant medications, participants must be on stable dosage for at least 3
             weeks prior to screening and should remain at a stable dosage during the course of the
             study.

          -  If on clozapine, quetiapine, and pimavanserin to address drug induced or disease
             related psychosis, participants must be on stable dosage for 3 weeks prior to
             screening and should remain at a stable dosage during the course of the study.

          -  If on antihypertensive medications, participants must be on stable dosage for at least
             3 weeks prior to screening.

          -  Men should use appropriate contraception.

          -  All participants must have a reliable caregiver who is in frequent contact with the
             participant (defined as at least 10 hours per week) and will accompany the participant
             to screening, baseline, day 7, day 42, day 84 and follow-up.

        Exclusion Criteria:

          -  Are women of childbearing potential.

          -  Have significant central nervous system or psychiatric disease, other than PD or DLB,
             that in the investigator's opinion may affect cognition or the ability to complete the
             study.

          -  Have a history in the last 6 months of transient ischemic attacks or ischemic stroke.

          -  Have a history of intra cerebral hemorrhage due to hypertension.

          -  Have a history of hypertensive encephalopathy.

          -  Have atypical or secondary parkinsonism due to drugs (e.g., antipsychotics) or disease
             (such as progressive supranuclear palsy, essential tremor, multiple system atrophy
             (e.g. striatonigral degeneration, olivopontocerebellar atrophy), or postencephalitic
             parkinsonism).

          -  Have a current implantable intracranial stimulator or history of intracranial ablation
             surgery (e.g., subthalamic, globus pallidus-internal segment [GPi]).

          -  Have a history of substance abuse within the past 1 year (drug categories defined by
             the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition [DSM-5], and/or
             substance dependence within the past 1 year, not including caffeine and nicotine.

          -  Have a serious or unstable medical illness, other than idiopathic LBD (PDD or DLB),
             including cardiovascular, hepatic, respiratory, hematologic, endocrinologic,
             neurologic, or renal disease, or clinically significant laboratory or
             electrocardiogram (ECG) abnormality as determined by the investigator.

               -  Have a history in the last 6 months of exertional angina, unstable angina,
                  myocardial infarction, and acute coronary syndrome.

               -  Have a history of heart failure of either New York Heart Association Class III or
                  IV.

               -  A history of additional risk factors for Torsades de Pointes (TdP; [e.g., chronic
                  hypokalemia, family history of Long QT Syndrome]).

          -  Participants with acute liver disease (e.g. acute viral hepatitis, alcoholic
             hepatitis); participants with a known chronic liver disease (e.g. hepatitis B, C,
             alcoholic liver disease, cirrhosis); alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) equal to or higher than 2X upper limit of normal (ULN); total
             bilirubin (TBL) equal to or higher than 1.5X ULN; (except for participants with
             Gilbert's syndrome); or alkaline phosphatase (ALP) equal to or higher than 2X ULN.

          -  Participants have answered 'yes' to either Question 4 (Active Suicidal Ideation with
             Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation
             with Specific Plan and Intent) on the &quot;Suicidal Ideation&quot; portion of the Columbia
             Suicide Severity Rating Scale (C-SSRS)- Children's version, or answer &quot;yes&quot; to any of
             the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt).

          -  Have used antipsychotic medications, with the exception of clozapine, quetiapine,
             pimavanserin in the 6 months prior to screening and at any time during the course of
             the study.

          -  Have used anticholinergics trihexyphenidyl and benztropine in the 4 weeks prior to
             screening and at any time during the course of the study.

          -  Have motor conditions for which the antiparkinsonian treatment is expected to change
             during the course of the study, as well as unpredictable motor fluctuations that in
             the investigator's opinion would interfere with administering assessments.

          -  Are taking any medications or food, herbal or dietary supplements that are inhibitors
             (e.g., ketoconazole, grapefruit juice), or strong/moderate inducers of cytochrome P450
             3A4 (CYP3A4) (e.g., rifampicin) or are unable or unwilling to discontinue usage of
             them 4 weeks prior to first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic of Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Health Sciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson'S &amp; Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CA, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network - CNS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Neuroscience Medical Group</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Neuroscience Health Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC3 Research Group Inc Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC3 Research Group Inc Reseda</name>
      <address>
        <city>Reseda</city>
        <state>California</state>
        <zip>91335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Neurological Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare Chase Movement Disorders Center</name>
      <address>
        <city>Vernon</city>
        <state>Connecticut</state>
        <zip>06066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Service</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norman Fixel Institute for Neurological Diseases (FIND)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinCloud, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIN - Victor Faradji</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collier Neurologic Specialists</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network -VIN-Margarita Almeida</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center of Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Neurology</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Neurological Associates, PC</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of NJ</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Disease and Memory Disorders Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adirondack Medical Research</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parker Jewish Insititue for Heatlh Care and Rehabilition</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Univ. Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Ins</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Professional Plaza</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison Hospital and Health Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Cruz Behavioral PSC</name>
      <address>
        <city>Bayamón</city>
        <zip>00961-6911</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cortex, PSC</name>
      <address>
        <city>Las Piedras</city>
        <zip>00771</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurologia Dra. Ivonne Fraga</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/parkinson-s-disease-dementia/HBEH#?postal=</url>
    <description>A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) (PRESENCE)</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease Dementia</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Cognition</keyword>
  <keyword>Lewy Body Dementia</keyword>
  <keyword>Dementia with Lewy Bodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

